Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Long-Term Investments (2019 - 2024)

Burning Rock Biotech has reported Long-Term Investments over the past 6 years, most recently at $35000.0 for Q3 2024.

  • For Q3 2024, Long-Term Investments fell 33.96% year-over-year to $35000.0; the TTM value through Sep 2024 reached $35000.0, down 33.96%, while the annual FY2023 figure was $47000.0, 53.0% down from the prior year.
  • Long-Term Investments for Q3 2024 was $35000.0 at Burning Rock Biotech, up from $34000.0 in the prior quarter.
  • Over five years, Long-Term Investments peaked at $250000.0 in Q2 2020 and troughed at $34000.0 in Q1 2024.
  • A 5-year average of $121331.7 and a median of $103008.4 in 2022 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: decreased 15.81% in 2020 and later tumbled 60.92% in 2024.
  • Year by year, Long-Term Investments stood at $213815.8 in 2020, then tumbled by 33.43% to $142332.7 in 2021, then tumbled by 31.84% to $97016.8 in 2022, then crashed by 51.76% to $46805.1 in 2023, then decreased by 25.22% to $35000.0 in 2024.
  • Business Quant data shows Long-Term Investments for BNR at $35000.0 in Q3 2024, $34000.0 in Q2 2024, and $34000.0 in Q1 2024.